Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial.

Abstract P1-11-21: Analysis of cognitive function in elderly HER2-positive breast cancer patients receiving either trastuzumab monotherapy or trastuzumab plus chemotherapy as a postoperative adjuvant treatment: A cognitive function sub-study of a randomized, open-label, phase 3 clinical trial (RESPECT trial)

10.1158/1538-7445.sabcs18-p1-11-21 ◽

2019 ◽

Author(s):

M Takahashi ◽

M Sawaki ◽

Y Hagiwara ◽

Y Uemura ◽

T Kawahara ◽

...

Keyword(s):

Breast Cancer ◽

Cognitive Function ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Trastuzumab Monotherapy ◽

Postoperative Adjuvant Treatment ◽

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30570-9 ◽

2018 ◽

Vol 19 (12) ◽

pp. 1630-1640 ◽

Cited By ~ 34

Author(s):

Mette S van Ramshorst ◽

Anna van der Voort ◽

Erik D van Werkhoven ◽

Ingrid A Mandjes ◽

Inge Kemper ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70178-0 ◽

2014 ◽

Vol 15 (7) ◽

pp. 689-699 ◽

Cited By ~ 350

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio González-Martín ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Versus Treatment

Abstract P6-17-14: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A multicenter, collaborative, open-label, phase II clinical trial for the SBCCSG-36 investigators

10.1158/1538-7445.sabcs18-p6-17-14 ◽

2019 ◽

Author(s):

K Inoue ◽

J Ninomiya ◽

K Okubo ◽

T Nakakuma ◽

H Yamada ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

223P Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2334 ◽

2020 ◽

Vol 31 ◽

pp. S330

Author(s):

A.J. ten Tije ◽

S. van Steenis ◽

J. Briers ◽

E.M.P. Elsten

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Final Analysis ◽

Injection Device ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Open Label Phase ◽

Single Use ◽

At Home

Faculty Opinions recommendation of Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718373656.793494835 ◽

2014 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Versus Treatment

Abstract PS13-12: Apatinib combined with taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, open-label, phase II trial

10.1158/1538-7445.sabcs20-ps13-12 ◽

2021 ◽

Author(s):

Yunjiang Liu ◽

Xiangmei Zhang ◽

Li Wang ◽

Miao Cao ◽

Shuo Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)00163-7 ◽

2016 ◽

Vol 17 (6) ◽

pp. 791-800 ◽

Cited By ~ 259

Author(s):

Luca Gianni ◽

Tadeusz Pienkowski ◽

Young-Hyuck Im ◽

Ling-Ming Tseng ◽

Mei-Ching Liu ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Randomised Trial ◽

Locally Advanced ◽

Phase 2 ◽

Her2 Positive ◽

Open Label ◽

Open Label Phase ◽

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30716-7 ◽

2018 ◽

Vol 19 (1) ◽

pp. 115-126 ◽

Cited By ~ 101

Author(s):

Sara A Hurvitz ◽

Miguel Martin ◽

W Fraser Symmans ◽

Kyung Hae Jung ◽

Chiun-Sheng Huang ◽

...

Keyword(s):

Breast Cancer ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Multicentre Phase ◽

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

The Lancet ◽

10.1016/s0140-6736(19)30653-1 ◽

2019 ◽

Vol 393 (10191) ◽

pp. 2591-2598 ◽

Cited By ~ 36

Author(s):

Xavier Pivot ◽

Gilles Romieu ◽

Marc Debled ◽

Jean-Yves Pierga ◽

Pierre Kerbrat ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Randomised Trial ◽

Final Analysis ◽

Open Label ◽

Phase 3 ◽

Adjuvant Trastuzumab ◽

Open Label Phase